Stock AnalizTandem Diabetes Care Inc. TNDM
Medical/Dental Instruments · IPO 2013 · data as of November 13, 2026
Tandem Diabetes Care Inc. (TNDM) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $1.1B and net income of -$49M, a net margin of -4.6%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 15% a year, a 5-year average ROIC of -13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 74% below the current price.
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.0B | $940M | $748M | $801M | $703M | $499M | $362M | $184M | $108M | $84M |
| Net income | -$49M | -$205M | -$96M | -$223M | -$95M | $16M | -$34M | -$25M | -$123M | -$73M | -$83M |
| Free cash flow | -$36M | -$30M | $5M | -$59M | $16M | $97M | -$3M | $22M | -$11M | -$72M | -$70M |
| EPS (diluted) | $-0.72 | $-3.04 | $-1.47 | $-3.43 | $-1.47 | $0.24 | $-0.56 | $-0.42 | $0.02 | $-12.87 | $-27.30 |
| Net margin | -4.6% | -20.2% | -10.2% | -29.8% | -11.8% | 2.2% | -6.9% | -6.8% | -66.7% | -67.9% | -99.1% |
| ROIC | — | -24.7% | -10.6% | -25.3% | -8.5% | 3.0% | -1.3% | -6.1% | -26.9% | -92.8% | -103.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 21 analysts is $26.90, 34% above the current price; targets range from $18.00 to $50.00; the consensus rating is “Buy”; expected EPS is $-0.60 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Tandem Diabetes Care stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 74% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Tandem Diabetes Care pay a dividend?
Not currently.
Is Tandem Diabetes Care a good stock to buy?
We do not give buy or sell advice. Tandem Diabetes Care scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.